Angiopoietin 2

So once you have it, it's a very efficient way to develop new products.

You know, you can imagine combination products that people suddenly say, hey, I really do think the anti-VEGF plus ANG2 inhibition or IL-6 inhibition is the way to go.

You can, with gene therapy, you can do combinations.

You can do multiple transgenes in the same product.

you know, to have some other target.

We saw that initially with ANG2.

And hopefully with Remigremig, there'll be some additional benefit for that 40% of patients that are the persistent edema patients and that this allows them to hit them with a different target, give us a little bit drier retinas.

And then the nice thing is, is our anti-VEGF should take care of progression of retinopathy.